BRIEF-Teva To Discontinue Phase 2 Topas-Msa Study Of Emrusolmin (Tev-‘286) Following Interim Futility Analysis

2

Nov 2 (Reuters) – Teva Pharmaceutical Industries Limited : * TEVA TO DISCONTINUE PHASE 2 TOPAS-MSA STUDY OF EMRUSOLMIN (TEV-‘286) FOLLOWING INTERIM FUTILITY ANALYSIS * TEVA – DECISION BASED ON INTERIM

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)